Summit X, LLC
- SEC CIK
- 0001697729
- Latest filing
- Nov 13, 2025
LCTX holding history
Lineage Cell Therapeutics, Inc. in every 13F filed by Summit X, LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
LCTX overviewAll 13F holders of LCTXFull Q3 2025 holdings
- Shares (Q4 2023)
- 0
- Sold out in Q4 2023
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 11
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q4 2023 | 0 | $0 | 0.0% | −10,925−100.0% | Sold out | Holders |
| Q3 2023 | 10,925 | $12.9K | <0.1% | −4,000−26.8% | Reduced | Holders |
| Q2 2023 | 14,925 | $21.0K | <0.1% | −7,000−31.9% | Reduced | Holders |
| Q1 2023 | 21,925 | $32.9K | <0.1% | −8,000−26.7% | Reduced | Holders |
| Q4 2022 | 29,925 | $47.3K | <0.1% | +5,000+20.1% | Added | Holders |
| Q3 2022 | 24,925 | $29.0K | <0.1% | −5,000−16.7% | Reduced | Holders |
| Q2 2022 | 29,925 | $48.0K | <0.1% | −1,000−3.2% | Reduced | Holders |
| Q1 2022 | 30,925 | $48.0K | <0.1% | −1,000−3.1% | Reduced | Holders |
| Q4 2021 | 31,925 | $78.0K | <0.1% | +3,000+10.4% | Added | Holders |
| Q3 2021 | 28,925 | $72.0K | <0.1% | −75−0.3% | Reduced | Holders |
| Q2 2021 | 29,000 | $82.0K | <0.1% | −3,000−9.4% | Reduced | Holders |
| Q1 2021 | 32,000 | $75.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.